Comparative Performance of the GeeniusTM HIV-1/HIV-2 Supplemental Test in Florida's Public Health Testing Population

Highlights • The Geenius HIV-1/HIV-2 Supplemental assay (Geenius) is the first non-subjective supplemental immunoassay in the confirmation process of an HIV infection. • Currently, Geenius is the only FDA cleared supplemental differentiating immunoassay in the U.S. • Based on this study, Geenius is...

Full description

Saved in:
Bibliographic Details
Published in:Journal of clinical virology 2017
Main Authors: Fordan, Sally, Bennett, Berry, Lee, Meghan, Crowe, Susanne
Format: Article
Language:English
Subjects:
Allergy and Immunology
Infectious Disease
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue
container_start_page
container_title Journal of clinical virology
container_volume
creator Fordan, Sally
Bennett, Berry
Lee, Meghan
Crowe, Susanne
description Highlights • The Geenius HIV-1/HIV-2 Supplemental assay (Geenius) is the first non-subjective supplemental immunoassay in the confirmation process of an HIV infection. • Currently, Geenius is the only FDA cleared supplemental differentiating immunoassay in the U.S. • Based on this study, Geenius is an appropriate replacement for the Multispot HIV-1/2 Differentiation assay (Multispot) and offers significant advantages over the subjective Multispot assay. • Based on this study, the use of Geenius as the primary supplemental assay in the 2014 HIV Diagnostic Algorithm may reduce the number of HIV-1 RNA NATs to resolve algorithm discordance but also illustrates the need for HIV-2 RNA NAT or an equivalent test to confirm HIV-2 infections.
doi_str_mv 10.1016/j.jcv.2017.04.005
format article
fullrecord <record><control><sourceid>elsevier</sourceid><recordid>TN_cdi_elsevier_clinicalkeyesjournals_1_s2_0_S1386653217301154</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S1386653217301154</els_id><sourcerecordid>1_s2_0_S1386653217301154</sourcerecordid><originalsourceid>FETCH-elsevier_clinicalkeyesjournals_1_s2_0_S13866532173011543</originalsourceid><addsrcrecordid>eNqlT71OwzAY9ABSC_QB2L6NKam__DKxVJQwIEVqxGqZ8IU6OHZkO5F4exLEG3S50-lOdzrG7pHHyLHY93HfznHCsYx5FnOeX7Etpo9FVORpsmE33vecY55m5ZaFgx1G6WRQM0FNrrNukKYlsB2EM8ELkVGTb96gen2PcL9iAqdpHDUNZILU0JAPoAwctXXqUz54qKcPrVqoSOpw_vOV-YLajpNehqy5Y9ed1J52_3zLno7PzaGKaBGzIidarYxqpf6mH_K9nZxZcgKFTwQXp_XM-gXLlCPmWXpxwS-CkGHQ</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Comparative Performance of the GeeniusTM HIV-1/HIV-2 Supplemental Test in Florida's Public Health Testing Population</title><source>Elsevier</source><creator>Fordan, Sally ; Bennett, Berry ; Lee, Meghan ; Crowe, Susanne</creator><creatorcontrib>Fordan, Sally ; Bennett, Berry ; Lee, Meghan ; Crowe, Susanne</creatorcontrib><description>Highlights • The Geenius HIV-1/HIV-2 Supplemental assay (Geenius) is the first non-subjective supplemental immunoassay in the confirmation process of an HIV infection. • Currently, Geenius is the only FDA cleared supplemental differentiating immunoassay in the U.S. • Based on this study, Geenius is an appropriate replacement for the Multispot HIV-1/2 Differentiation assay (Multispot) and offers significant advantages over the subjective Multispot assay. • Based on this study, the use of Geenius as the primary supplemental assay in the 2014 HIV Diagnostic Algorithm may reduce the number of HIV-1 RNA NATs to resolve algorithm discordance but also illustrates the need for HIV-2 RNA NAT or an equivalent test to confirm HIV-2 infections.</description><identifier>ISSN: 1386-6532</identifier><identifier>DOI: 10.1016/j.jcv.2017.04.005</identifier><language>eng</language><subject>Allergy and Immunology ; Infectious Disease</subject><ispartof>Journal of clinical virology, 2017</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids></links><search><creatorcontrib>Fordan, Sally</creatorcontrib><creatorcontrib>Bennett, Berry</creatorcontrib><creatorcontrib>Lee, Meghan</creatorcontrib><creatorcontrib>Crowe, Susanne</creatorcontrib><title>Comparative Performance of the GeeniusTM HIV-1/HIV-2 Supplemental Test in Florida's Public Health Testing Population</title><title>Journal of clinical virology</title><description>Highlights • The Geenius HIV-1/HIV-2 Supplemental assay (Geenius) is the first non-subjective supplemental immunoassay in the confirmation process of an HIV infection. • Currently, Geenius is the only FDA cleared supplemental differentiating immunoassay in the U.S. • Based on this study, Geenius is an appropriate replacement for the Multispot HIV-1/2 Differentiation assay (Multispot) and offers significant advantages over the subjective Multispot assay. • Based on this study, the use of Geenius as the primary supplemental assay in the 2014 HIV Diagnostic Algorithm may reduce the number of HIV-1 RNA NATs to resolve algorithm discordance but also illustrates the need for HIV-2 RNA NAT or an equivalent test to confirm HIV-2 infections.</description><subject>Allergy and Immunology</subject><subject>Infectious Disease</subject><issn>1386-6532</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNqlT71OwzAY9ABSC_QB2L6NKam__DKxVJQwIEVqxGqZ8IU6OHZkO5F4exLEG3S50-lOdzrG7pHHyLHY93HfznHCsYx5FnOeX7Etpo9FVORpsmE33vecY55m5ZaFgx1G6WRQM0FNrrNukKYlsB2EM8ELkVGTb96gen2PcL9iAqdpHDUNZILU0JAPoAwctXXqUz54qKcPrVqoSOpw_vOV-YLajpNehqy5Y9ed1J52_3zLno7PzaGKaBGzIidarYxqpf6mH_K9nZxZcgKFTwQXp_XM-gXLlCPmWXpxwS-CkGHQ</recordid><startdate>2017</startdate><enddate>2017</enddate><creator>Fordan, Sally</creator><creator>Bennett, Berry</creator><creator>Lee, Meghan</creator><creator>Crowe, Susanne</creator><scope/></search><sort><creationdate>2017</creationdate><title>Comparative Performance of the GeeniusTM HIV-1/HIV-2 Supplemental Test in Florida's Public Health Testing Population</title><author>Fordan, Sally ; Bennett, Berry ; Lee, Meghan ; Crowe, Susanne</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-elsevier_clinicalkeyesjournals_1_s2_0_S13866532173011543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Allergy and Immunology</topic><topic>Infectious Disease</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fordan, Sally</creatorcontrib><creatorcontrib>Bennett, Berry</creatorcontrib><creatorcontrib>Lee, Meghan</creatorcontrib><creatorcontrib>Crowe, Susanne</creatorcontrib><jtitle>Journal of clinical virology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fordan, Sally</au><au>Bennett, Berry</au><au>Lee, Meghan</au><au>Crowe, Susanne</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparative Performance of the GeeniusTM HIV-1/HIV-2 Supplemental Test in Florida's Public Health Testing Population</atitle><jtitle>Journal of clinical virology</jtitle><date>2017</date><risdate>2017</risdate><issn>1386-6532</issn><abstract>Highlights • The Geenius HIV-1/HIV-2 Supplemental assay (Geenius) is the first non-subjective supplemental immunoassay in the confirmation process of an HIV infection. • Currently, Geenius is the only FDA cleared supplemental differentiating immunoassay in the U.S. • Based on this study, Geenius is an appropriate replacement for the Multispot HIV-1/2 Differentiation assay (Multispot) and offers significant advantages over the subjective Multispot assay. • Based on this study, the use of Geenius as the primary supplemental assay in the 2014 HIV Diagnostic Algorithm may reduce the number of HIV-1 RNA NATs to resolve algorithm discordance but also illustrates the need for HIV-2 RNA NAT or an equivalent test to confirm HIV-2 infections.</abstract><doi>10.1016/j.jcv.2017.04.005</doi></addata></record>
fulltext fulltext
identifier ISSN: 1386-6532
ispartof Journal of clinical virology, 2017
issn 1386-6532
language eng
recordid cdi_elsevier_clinicalkeyesjournals_1_s2_0_S1386653217301154
source Elsevier
subjects Allergy and Immunology
Infectious Disease
title Comparative Performance of the GeeniusTM HIV-1/HIV-2 Supplemental Test in Florida's Public Health Testing Population
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T18%3A49%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparative%20Performance%20of%20the%20GeeniusTM%20HIV-1/HIV-2%20Supplemental%20Test%20in%20Florida's%20Public%20Health%20Testing%20Population&rft.jtitle=Journal%20of%20clinical%20virology&rft.au=Fordan,%20Sally&rft.date=2017&rft.issn=1386-6532&rft_id=info:doi/10.1016/j.jcv.2017.04.005&rft_dat=%3Celsevier%3E1_s2_0_S1386653217301154%3C/elsevier%3E%3Cgrp_id%3Ecdi_FETCH-elsevier_clinicalkeyesjournals_1_s2_0_S13866532173011543%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true